Drug InteractionsAbiraterone is a potential inhibitor of CYP isoenzymes 1A2, 2D6, and 2C8 and, to a lesser extent, CYP isoenzymes 2C9, 2C19, and 3A4/5. Abiraterone is a substrate of CYP3A4 in vitro.Neither abiraterone acetate nor abiraterone is a substrate of P-glycoprotein (P-gp) ...
drug resistanceMDV3100prostate cancerBedoya DJ, Mitsiades N.doi:10.1586/era.11.196Bedoya, Diego JMitsiades, NicholasExpert Review of Anticancer TherapyMontgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-...
Akeega (Abiraterone/Niraparib) Drug Label Information. Horsham, PA: Janssen Biotech; 2023. About Dr. Gerardo Sison (Page Author) Dr. Sison graduated with honors from the University of Florida. He began his career in pharmacy counseling patients in a community setting and later served in hosp...
Drugs That Inhibit or Induce CYP3A4 Enzymes -Based onin vitrodata, ZYTIGA®is a substrate of CYP3A4. In a drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA®treat...
YONSA(abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With MethylprednisoloneU.S. Food and Drug Administration (FDA) for YONSA® (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic cast...
Effects of AA are reproducible in a host-free gut model. Next, to deconvolute the complexity of deciphering microbe–drug interactions over time in the human body, we utilized a simulated model of the human distal gut microbiota to simulate AA exposure in the context of a stabilized ...
Ketoconazole, previously studied as an inhibitor of the 14α-demethylase, shows nonselective inhibition toward several CYP enzymes including CYP17A1. In spite of its toxicity, associated to indiscriminate CYP inhibition, this drug is still employed in several countries for the treatment of prostate ...
Here we report X-ray crystal structures of CYP17A1, which were obtained in the presence of either abiraterone, a first-in-class steroidal inhibitor recently approved by the US Food and Drug Administration for late-stage prostate cancer, or TOK-001, an inhibitor that is currently undergoing ...
DRUG INTERACTIONS CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during abiraterone acetate treatment. If a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate dosing frequency. (2.5, 7.1) CYP2D6 Substrates: Avoid co-administration of abiraterone acetate with ...
Furthermore, the clinical success of abiraterone demonstrated that CRPC, which has previously been regarded as an androgen-independent disease, is still driven, at least in part, by androgens. More importantly, abiraterone is a 'promiscuous' drug that interacts with a number of targets, which ...